Increased homocysteine plasma level is associated with shortened prothrombin time in HIV-infected patients

References

• Lewden C, Bouteloup V, De Wit S, et al. Collaboration of observational HIV epidemiological research Europe (COHERE) in Eurocoord. All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol. 2012;41:433–445.
   PubMed Web of Science ®Google Scholar
• Weber R, Ruppik M, Rickenbach M, et al. Decreasing mortality and changing patterns of causes of death in the Swiss HIV cohort study. HIV Med. 2013;14:195–207.10.1111/hiv.2013.14.issue-4
   PubMed Web of Science ®Google Scholar
• Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of health and human services. Last updated: 5/1/2014. Available from: http://aidsinfo.nih.gov/g0075idelines. Accessed June 3, 2014.
   Google Scholar
• Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society–USA panel. JAMA. 2012;308:387–402.
   PubMed Web of Science ®Google Scholar
• Fichtenbaum CJ. Metabolic abnormalities associated with HIV infection and antiretroviral therapy. Curr Infect Dis Rep. 2009;11:84–92.10.1007/s11908-009-0012-8
   PubMedGoogle Scholar
• The Data collection on adverse events of anti-HIV. Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993–2003.
   Google Scholar
• Domingo P, Suarez-Lozano I, Teira R, et al. Dyslipidemia and cardiovascular disease risk factor management in HIV-1-infected subjects treated with HAART in the Spanish VACH cohort. Open AIDS J. 2008;2:26–38.10.2174/1874613600802010026
   PubMedGoogle Scholar
• Chan D, Gracey D, Bailey M, et al. Screening and management of cardiovascular disease in Australian adults with HIV infection. Sex Health. 2013;10:495–501.10.1071/SH13009
   PubMed Web of Science ®Google Scholar
• Schalinske KL, Smazal AL. Homocysteine imbalance: a pathological metabolic marker. Adv Nutr. 2012;3:755–762.10.3945/an.112.002758
   PubMed Web of Science ®Google Scholar
• Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil. 2007;14(Suppl 2):S1–113.10.1097/01.hjr.0000277983.23934.c9
   PubMed Web of Science ®Google Scholar
• Humphrey LL, Fu R, Rogers K, et al. Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis. Mayo Clin Proc. 2008;83:1203–1212.10.4065/83.11.1203
   PubMed Web of Science ®Google Scholar
• Yang Q, Botto LD, Erickson JD, et al. Improvement in stroke mortality in Canada and the United States, 1990 to 2002. Circulation. 2006;113:1335–1343.10.1161/CIRCULATIONAHA.105.570846
   PubMed Web of Science ®Google Scholar
• Ebbing M, Bleie Ø, Ueland PM, et al. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial. JAMA. 2008;300:795–804.10.1001/jama.300.7.795
   PubMed Web of Science ®Google Scholar
• Albert CM, Cook NR, Gaziano JM, et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA. 2008;299:2027–2036.10.1001/jama.299.17.2027
   PubMed Web of Science ®Google Scholar
• Bønaa KH, Njølstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354:1578–1588.10.1056/NEJMoa055227
   PubMed Web of Science ®Google Scholar
• Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354:1567–1577.
   PubMed Web of Science ®Google Scholar
• Antoniades C, Antonopoulos AS, Tousoulis D, et al. Homocysteine and coronary atherosclerosis: from folate fortification to the recent clinical trials. Eur Heart J. 2008;30:6–15.10.1093/eurheartj/ehn515
   PubMed Web of Science ®Google Scholar
• Clarke R, Bennett DA, Parish S, et al. Homocysteine and coronary heart disease: meta-analysis of MTHFR case-control studies, avoiding publication bias. PLoS Med. 2012;9:e1001177.10.1371/journal.pmed.1001177
   PubMed Web of Science ®Google Scholar
• Roca B, Bennasar M, Ferrero JA, et al. Hepatitis C virus co-infection and sexual risk behaviour are associated with a high homocysteine serum level in HIV-infected patients. Swiss Med Wkly. 2012;141:w13323.
   PubMedGoogle Scholar
• Selhub J. Public health significance of elevated homocysteine. Food Nutr Bull. 2008;29(2 Suppl):S116–25.10.1177/15648265080292S116
   PubMed Web of Science ®Google Scholar
• Murphy MM, Fernandez-Ballart JD. Homocysteine in pregnancy. Adv Clin Chem. 2011;53:105–137.10.1016/B978-0-12-385855-9.00005-9
   PubMed Web of Science ®Google Scholar
• Guaraldi G, Ventura P, Garlassi E, et al. Hyperhomocysteinaemia in HIV-infected patients: determinants of variability and correlations with predictors of cardiovascular disease. HIV Med. 2009;10:28–34.10.1111/hiv.2008.10.issue-1
   PubMed Web of Science ®Google Scholar
• Bernasconi E, Uhr M, Magenta L, et al. Homocysteinaemia in HIV-infected patients treated with highly active antiretroviral therapy. The Swiss HIV cohort study. AIDS. 2001;15:1081–1082.
   PubMed Web of Science ®Google Scholar
• Bongiovanni M, Casana M, Pisacreta M, et al. Predictive factors of hyperhomocysteinemia in HIV-positive patients. J Acquir Immune Defic Syndr. 2007;44:117–119.10.1097/QAI.0b013e31802be3e8
   PubMed Web of Science ®Google Scholar
• Uccelli MC, Torti C, Lapadula G, et al. Influence of folate serum concentration on plasma homocysteine levels in HIV-positive patients exposed to protease inhibitors undergoing HAART. Ann Nutr Metab. 2006;50:247–252.10.1159/000091682
   PubMed Web of Science ®Google Scholar
• Deminice R, Vassimon HS, Machado AA, et al. Plasma homocysteine levels in HIV-infected men with and without lipodystrophy. Nutrition. 2013;29:1326–1330.10.1016/j.nut.2013.04.017
   PubMed Web of Science ®Google Scholar
• Abdollahi A, Shoar TS. Hyperhomocysteinemia in HIV-infected individuals: correlation of a frequent prothrombotic factor with CD4+ cell count. Oman Med J. 2012;27:224–227.10.5001/omj.2012.50
   PubMedGoogle Scholar
• Sule AA, Pandit N, Handa P, et al. A case series of HIV-seropositive patients and hypercoagulable state-is it difficult to treat even with therapeutic anticoagulation? Int J Angiol. 2013;22:105–108.
   PubMedGoogle Scholar
• Basavanagowdappa H, Babu MS, Karuturi S. HIV infection and thromboembolism. J Assoc Physicians India. 2011;59:380–382.
   PubMedGoogle Scholar
• Phillippe HM, Hornsby LB, Treadway S, et al. Inherited thrombophilia. J Pharm Pract. 2014;27:227–233.10.1177/0897190014530390
   PubMedGoogle Scholar
• Remacha AF, Souto JC, Piñana JL, et al. Vitamin B12 deficiency, hyperhomocysteinemia and thrombosis: a case and control study. Int J Hematol. 2011;93:458–464.10.1007/s12185-011-0825-8
   PubMed Web of Science ®Google Scholar
• Fay WP. Homocysteine and thrombosis: guilt by association? Blood. 2012;119:2977–2978.10.1182/blood-2012-01-401513
   PubMed Web of Science ®Google Scholar
• Pontrelli G, Martino AM, Tchidjou HK, et al. HIV is associated with thrombophilia and high D-dimer in children and adolescents. AIDS. 2010;24:1145–1151.10.1097/QAD.0b013e328337b9a0
   PubMed Web of Science ®Google Scholar
• Ruan L, Chen W, Srinivasan SR, et al. Plasma homocysteine is adversely associated with glomerular filtration rate in asymptomatic black and white young adults: the Bogalusa heart study. Eur J Epidemiol. 2009;24:315–319.10.1007/s10654-009-9340-0
   PubMed Web of Science ®Google Scholar
• Haynes R, Clarke R. Homocysteine, the kidney, and vascular disease. BMJ. 2012;344:e3925.10.1136/bmj.e3925
   PubMed Web of Science ®Google Scholar
• Garibotto G, Sofia A, Valli A, et al. Causes of hyperhomocysteinemia in patients with chronic kidney diseases. Semin Nephrol. 2006;26:3–7.10.1016/j.semnephrol.2005.06.002
   PubMed Web of Science ®Google Scholar
• Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007;116:85–97.10.1161/CIRCULATIONAHA.106.678342
   PubMed Web of Science ®Google Scholar
• Rodionov RN, Lentz SR. The homocysteine paradox. Arterioscler Thromb Vasc Biol. 2008;28:1031–1033.10.1161/ATVBAHA.108.164830
   PubMed Web of Science ®Google Scholar
• Yakub M, Schulze KJ, Khatry SK, et al. High plasma homocysteine increases risk of metabolic syndrome in 6 to 8 year old children in rural Nepal. Nutrients. 2014;6:1649–1661.10.3390/nu6041649
   PubMed Web of Science ®Google Scholar
• Chen SF, Cui CL, Wu P, et al. Relationship of serum homocysteine level with nutritional status and HbA1c level in elderly in patients. Int J Clin Exp Med. 2013;6:779–784.
   PubMed Web of Science ®Google Scholar
• Famularo G, Barracchini A, Minisola G. Severe thrombophilia with antiphospholipid syndrome and hyperhomocysteinemia in a patient with Schnitzler’s syndrome. Clin Exp Rheumatol. 2003;21:366–368.
   PubMed Web of Science ®Google Scholar